Pfizer Oncology Deal History & Licensing Activity
Pfizer Oncology is a large pharma headquartered in US. Over the past three years, Pfizer Oncology has been involved in 10 licensing and acquisition transactions, with a primary focus on Small Molecules (3 deals). The company currently has 11 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
7
Active Trials
11
Top Modality
Small Molecules
Focus Area
Solid Tumors
Pfizer Oncology Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Pfizer Oncology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| SSGJ-707 / PF-08634404 | Pfizer | Bispecific Antibodies | Phase 3 | license | Mar 2026 |
| ecnoglutide | Pfizer | Peptides | Approved | license | Feb 2026 |
| solid tumors | Pfizer | BispecificAntibody | Phase 2 | license | Jul 2025 |
Pfizer Oncology Pipeline Focus
Therapeutic areas and modalities where Pfizer Oncology is most active based on deal history and clinical trial data.
Therapeutic Areas
Pfizer Oncology Strategic Signals
Key indicators of Pfizer Oncology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Pfizer Oncology Clinical Pipeline
Pfizer Oncology has 11 active clinical trials across 4 development phases.
1
Unknown
2
Phase 1
7
Phase 2
1
Phase 3
See How Your Asset Matches Pfizer Oncology's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Pfizer Oncology Licensing & Deal Activity
Pfizer Oncology is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 10 deals over the past three years, Pfizer Oncology ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Pfizer Oncology include Solid Tumors (6 deals and trials), Oncology (5 deals and trials), Hematological Malignancies (4 deals and trials), and Gastroenterology (3 deals and trials). In terms of modality, Pfizer Oncology has shown particular interest in small molecules, bispecific antibodies, peptides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Pfizer Oncology and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Pfizer Oncology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.